article
Latest
Most Read
article
Weekends
U.S. Vaccinations Stall; Beijing Reports Omicron: Virus Update
Glaxo Rejects $68 Billion Unilever Bid for Consumer Business
Fed Needs Half-Point Rate Hike to Regain Credibility: Ackman
Louvre Blasts Le Pen Video as French Presidential Race Heats Up
EU Targets Fictitious Finnish Power Company in Cyberattack Test
Australia Says Djokovic’s Vaccination Stance Poses a Public Risk
LSE Proposes Special Market for Private Companies, WSJ Reports
Apple Will Allow Outside Payments in Dutch Dating Apps
Live
Live on Bloomberg TV
Bloomberg Studio 1.0
Why GameFi Is Crypto’s Hot New Thing (and What Is It?)
France’s Nuclear Champion Sacrificed to Stave Off Energy Crisis
Tsunami Threat Recedes From Huge Pacific Volcanic Eruption
Italy Bans Truffle Hunting After Swine Fever Outbreak Poses Risk
LA Looters Raid Unattended Containers Amid Supply-Chain Chaos
Opinion
Chris Hughes
Unilever's $68 Billion Toothpaste Tilt Needs Another Squeeze
There’s strategic sense in the consumer giant’s bid for GlaxoSmithKline’s healthcare arm. Paying a winning price is the real challenge.
Brooke Sample
The Virus Has Changed. Maybe We Should, Too.
Our defenses against Covid-19 and variants like omicron have improved dramatically since the beginning of the pandemic. Let’s live accordingly.
Noah Feldman
Gorsuch v. the Administrative State Is Really Heating Up
Three Supreme Court conservatives have signaled that they want to go beyond barring vaccine mandates to erecting sweeping constitutional barriers against federal regulatory activity.
Therese Raphael
Does Novak Djokovic Really Pose a Health Risk in Australia?
The saga of the world’s number one tennis player should highlight limits on the use of draconian border controls at this stage of the pandemic.
Clara Ferreira Marques
China and Russia Have a Central Asia Problem
During Kazakhstan’s recent unrest, Moscow and Beijing seemed to slip into their conventional roles in the region — the “gun” and the “wallet.” But that equilibrium won’t hold.
Opinion
Chris Hughes
Unilever's $68 Billion Toothpaste Tilt Needs Another Squeeze
There’s strategic sense in the consumer giant’s bid for GlaxoSmithKline’s healthcare arm. Paying a winning price is the real challenge.
Brooke Sample
The Virus Has Changed. Maybe We Should, Too.
Our defenses against Covid-19 and variants like omicron have improved dramatically since the beginning of the pandemic. Let’s live accordingly.
Noah Feldman
Gorsuch v. the Administrative State Is Really Heating Up
Three Supreme Court conservatives have signaled that they want to go beyond barring vaccine mandates to erecting sweeping constitutional barriers against federal regulatory activity.
Therese Raphael
Does Novak Djokovic Really Pose a Health Risk in Australia?
The saga of the world’s number one tennis player should highlight limits on the use of draconian border controls at this stage of the pandemic.
Clara Ferreira Marques
China and Russia Have a Central Asia Problem
During Kazakhstan’s recent unrest, Moscow and Beijing seemed to slip into their conventional roles in the region — the “gun” and the “wallet.” But that equilibrium won’t hold.
